Genetic susceptibility and the occurrence of Parkinson's disease

Parkinsonism and Related Disorders

Volumn 5, Issue 4, 1999, Pages 173-177

  Jenner, P ^a  

^a G   (United Kingdom)

Author keywords

Environment; Genetic causes; Interaction; Parkinson's disease; Susceptibility genes

Indexed keywords

CELL DEGENERATION; ENVIRONMENTAL FACTOR; GENETIC SUSCEPTIBILITY; HUMAN; MONOZYGOTIC TWINS; PARKINSONISM; PREVALENCE; PRIORITY JOURNAL; REVIEW; TWINS;

EID: 0032838840     PISSN: 13538020     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1353-8020(99)00034-6     Document Type: Article

References (59)

1. Forno L.S. Pathology of Parkinson's disease. Marsden C.D., Fahn S. Movement disorders. 1982;25-40.
2. Jenner P., Olanow C.W. Understanding cell death in Parkinson's disease. Olanow C.W., Jenner P. Beyond the decade of the brain. 1998;145-166 Wells Medical, Royal Tunbridge Wells.
3. Olanow C.W., Jenner P., Tatton N.A., Tatton W.G. Neurodegeneration and Parkinson's disease. Jankovic J., Tolosa E. Parkinson's disease and movement disorders. 1998;67-103 Williams & Wilkie, Baltimore.
4. Golbe L. The genetics of Parkinson's disease: a reconsideration. Neurology. 40:1990;7-14.
5. Gasser T. Genetics of Parkinson's disease. Clin Genet. 54:1998;259-265.
6. Tanner C.M., Langston J.W. Do environmental toxins cause Parkinson's disease? A critical review. Neurology. 40:1990;17-30.
7. Golbe L.I., Di Iorio G., Bonavita V., Miller D.C., Duvoisin R.C. A large kindred with autosomal dominant Parkinson's disease. Ann Neurol. 27:1990;276-282.
8. Tanner C.M., Ottman R., Ellenberg J.H., et al. Parkinson's disease (PD) concordance in elder male monozygotic (MZ) and dizygotic (DZ) twins. Neurology. 48:1997;333.
9. Wood N.W. Genetic risk factors in Parkinson's disease. Ann Neurol. 1:(3 (Suppl. 1)):1998;S58-S62.
10. Polymeropoulos M.J., Lavedan C., Leroy E., Ide S.E., Dehejia A., Dutra A., et al. Mutation in the α-synuclein gene identified in families with Parkinson's disease. Science. 276:1997;2045-2047.
11. Kruger R., Kuhn W., Muller T., et al. Ala30Pro mutation in the gene encoding α-synuclein in Parkinson's disease. Nat Genet. 18:1998;106-108.
12. Leroy E., Boyer R., Auburger G., Leube B., Ulm G., Mezey E., Harta G., Brownstein M.J., Jonnalagada S., Chernova T., Dehejia A., Lavedan C., Gasser T., Steinbach P.J., Wilkinson K.D., Polymeropoulos M.H. The ubiquitin pathway in Parkinson's disease. Nature. 395:1998;451-452.
13. Gasser T., Muller-Myhsok B., Wszolek Z.K., Oehlmann R., Calne D.B., Bonifati V., Bereznai R., Fabrizio E., Vieregge P., Horstmann R.D. A susceptibility locus for Parkinson's disease maps to chromosome 2p13. Nat Genet. 18:1998;262-265.
14. Vaughan J., Durr A., Tassin J., Bereznai B., Gasser T., Bonifati V., De Michele G., Fabrizio E., Volpe G., Bandmann O., Johnson W.G., Golbe L.I., Breteler M., Meco G., Agid Y., Brice A., Marsden C.D., Wood N.W. The α-synuclein Ala53Thr mutation is not a common cause of familial Parkinson's disease: a study of 230 European cases. Ann Neurol. 44:1998;270-273.
15. El-Agnaf O.M.A., Curran M.D., Wallace A., Middleton D., Murgatroyd C., Curtis A., Perry R., Jaros E. Mutation screening in exons 3 and 4 of α-synuclein in sporadic and familial dementia with Lewy bodies cases. Neuroreport. 9:1998;3925-3927.
16. Chan P., Tanner C.M., Jiang X., Langston J.W. Failure to find the α-synuclein gene missense mutation (G209A) in 100 patients with younger onset Parkinson's disease. Neurology. 50:1998;513-514.
17. Higuchi S., Arai H., Matsushita S., Matsui T., Kimpara T., Takeda A., Shirakura K. Mutation in the α-synuclein gene and sporadic Parkinson's disease, Alzheimer's disease, and dementia with Lewy bodies. Exp Neurol. 153:1998;164-166.
18. Wakabayashi K., Hayashi S., Kakita A., Yamada M., Toyoshima Y., Yoshimoto M., Takahashi H. Accumulation of α-synuclein/NACP is a cytopathological feature common to Lewy body disease and multiple system atrophy. Acta Neuropathol. 96:1998;445-452.
19. Spillantini M.G., Crowther R.A., Jakes R., Cairns N.J., Lantos P.L., Goedert M. Filamentous α-synuclein inclusions link multiple system atrophy with Parkinson's disease and dementia with Lewy bodies. Neurosci Lett. 251:1998;205-208.
20. Mezey E., Dahejia A.M., Harta G., Suchy S.F., Nussbaum R.L., Browstein M.J., Polymeropoulos M.H. α-Synuclein is present in Lewy bodies in sporadic Parkinson's disease. Mol Psychiat. 3:1998;493-499.
21. Golbe L.I. α-Synuclein and Parkinson's disease. Mov Disord. 14:1999;6-9.
22. Marsden C.D. Parkinson's disease in twins. J Neurol Neurosurg Psychiat. 50:1987;105-106.
23. 18F-dopa and positron emission tomography. Neurology. 42:1992;1894-1900.
24. Piccini P., Burn D.J., Ceravolo R., Maraganore D., Brooks D.J. The role of inheritance in sporadic Parkinson's disease: evidence from a longitudinal study of dopaminergic function in twins. Ann Neurol. 1999;45.
25. Tanner C.M., Ottman R., Goldman S.M., Ellenberg J., Chan P., Mayeux R., Langston J.W. Parkinson's disease in twins: an etiology study. Jama. 28:1999;341-346.
26. Alonso M.E., Otero E., D'Regules R., Figueroa H.H. Parkinson's disease: a genetic study. Can J Neurol Sci. 13:1986;248-251.
27. Martin W.E., Young W., Anderson V.E. Parkinson's disease. A genetic study. Brain. 96:1973;495-506.
28. Duvoisin R.C., Gearing I.R., Schweitzer M.R., Yahr M.D. A family study of parkinsonism. Barbeau A., Brunette J.R. Progress in neurogenetics. 1969;492-496 Excerpta Medica Foundation, Amsterdam.
29. Semchuk K.M., Love E.J., Lee R.G. Parkinson's disease: a test of the multifactorial etiologic hypothesis. Neurology. 43:1993;1173-1180.
30. Vieregge P., Schiffke K.A., Friedrich H.J., et al. Parkinson's disease in twins. Neurology. 42:1992;1453-1461.
31. Marttila R.J., Rinne U.K. Arteriosclerosis, hereditary and some previous infections in the etiology of Parkinson's disease. A case-control study. Clin Neurol Neurosurg. 79:1976;46-56.
32. Lazzarini A.M., Myers R.H., Zimmerman T.R. Jr, Mark M.H., Golbe L.I., Sage J.I., Johnson W.G., Duvoisin R.C. A clinical genetic study of Parkinson's disease: evidence for dominant transmission. Neurology. 44:1994;499-506.
33. Uiti R.J., Shinotoh H., Hayward M., Schulzer M., Mak E., Calne D.B. Familial Parkinson's disease - a case-control study of families. Can J Neurol. 24:1997;127-132.
34. Gasser T., Wszolek Z.K., Trofatter J., Ozelius L., Uitti R.J., Lee C.S., Gusella J., Pfeiffer R.F., Calne D.B., Breakefield X.O. Genetic linkage studies in autosomal dominant parkinsonism: evaluation of seven candidate genes. Ann Neurol. 36:1994;387-396.
35. Checkoway H., Farin F.M., Costa-Mallen P., Kirchner S.C., Costa L.G. Genetic polymorphisms in Parkinson's disease. Neurotoxicology. 19:1998;635-644.
36. Bandmann O., Vaughan J., Marsden C.D., Wood N.W. Association of slow acetylation genotype for N-acetyltransferase 2 with familial Parkinson's disease. Lancet. 350:1997;1136-1139.
37. Agundez J.A.G., Jimenez-Jimenez F.J., Luengo A., Molina J.A., Orti-Pareja M., Vazquez A., Ramos F., Duarte J., Coria F., Ladero J.M., Alvarez-Cermeno J.C., Benitez J. Slow allotypic variants of the NAT2 gene and susceptibility of early-onset Parkinson's disease. Neurology. 51:1998;1587-1592.
38. Barbeau A., Roy M., Paris S., Cloutier T., Plasse L., Poirier J. Ecogenetics of Parkinson's disease: 4-hydroxylation of debrisoquinine. Lancet. 2:1985;1213-1216.
39. Poirier J., Roy M., Campanella G., Cloutier T., Paris S. Debrisoquine metabolism in parkinsonian patients treated with antihistamine drugs. Lancet. 2:1987;386.
40. Coleman T., Ellis S.W., Martin I.J., Lennard M.S., Tucker G.T. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) is N-demethylated by cytochrome P450 2D6, 1A2 and 3A4 - implications for susceptibility to Parkinson's disease. J Pharmacol Exp Theor. 277:1996;685-690.
41. Fonne-Pfister R., Bargetzi M.J., Meyer U.S. MPTP, the neurotoxin inducing Parkinson's disease, is a potent inhibitor of human and rat cytochrome P450 isozymes (P450bufl, P450dbl) catalyzing debrisoquinine-4-hydroxylation. Biochem Biophys Res Commun. 148:1987;1144-1150.
42. Riedl A.G., Watts P.M., Jenner P., Marsden C.D. P450 enzymes and Parkinson's disease: the story so far. Mov Disord. 13:1998;212-220.
43. McCann S.J., Pond S.M., James K.M., Le Couteur D.G. The association between polymorphisms in the cytochrome P-450 2D6 gene and Parkinson's disease: a case-control study and meta-analysis. J Neurol Sci. 153:1997;50-53.
44. Sabbagn N., Brice A., Marez D., Durr A., Legrand M., Lo Guidice J.-M., Destee A., Agid Y., Broly F. CYP2D6 polymorphism and Parkinson's disease susceptibility. Mov Disord. 12:1999;230-236.
45. Schoenberg B.S. Environmental risk factors for Parkinson's disease: the epidemiologic evidence. Can J Neurol Sci. 14:1987;407-413.
46. Tanner C.M., Chen B., Wang W.-Z., Peng M.-L., Liu Z.-L., Liang X.-L., Kao L.C., Gilley D.W., Schoenberg B.S. Environmental factors in the etiology of Parkinson's disease. Can J Neurol Sci. 14:1987;419-423.
47. Rajput A.H., Uitti R.J., Stern W., Laverty W., O'Donnell K., O'Donnell D., Yuen W.K., Dua A. Geography, drinking water chemistry, pesticides and herbicides and the etiology of Parkinson's disease. Can J Neurol Sci. 14:1987;414-418.
48. Gorell J.M., Johnson C.C., Rybicki B.A., Peterson E.L., Richardson R.J. The risk of Parkinson's disease with exposure to pesticides, farming, well water, and rural living. Neurology. 50:1998;1346-1350.
49. Fall P.A., Fredrikson M., Axelson O., Granerus A.k. Nutritional and occupational factors influencing the risk of Parkinson's disease: a case-control study in southeastern Sweden. Mov Disord. 14:1999;28-37.
50. Langston J.W., Ballard P., Tetrud J.W., Irwin I. Chronic parkinsonism in humans due to a product of meperidine-analog synthesis. Science. 219:1983;979-980.
51. Burns R.S., Chiueh C.C., Markey S.P., Ebert M.H., Jacobowitz D.M., Kopin I.J. A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Proc Natl Acad Sci USA. 80:1983;4546-4550.
52. McNaught K.S.t.P., Carrupt P.-A., Altomare C., Cellamare S., Carotti A., Testa B., Jenner P., Marsden C.D. Isoquinoline derivatives as endogenous neurotoxins in the aetiology of Parkinson's disease. Biochem Pharmacol. 56:1998;921-933.
53. Pezzoli G., Barbieri A.S., Canesi M., Perbellini L., Zecchinelli A., Mariani C.B., Bonetti A., Leenders K.L. n-Hexane-induced parkinsonism: pathogenetic hypotheses. Mov Disord. 10:1995;279-282.
54. Lee M.S., Marsden C.D. Neurological sequelae following carbon monoxide poisoning, clinical course and outcome according to the clinical types and computed tomography scan findings. Mov Disord. 9:1994;550-558.
55. Sanchez-Ramos J.R. Toxin-induced parkinsonism. Stern M.B., Koller W.D. Parkinsonian syndromes. 1993;155-171 Marcel Dekker, New York.
56. Yamada M., Ohno S., Okayasu I., Hatakeyama S., Watanabe H., Ushio K., Tsukagoshi H. Chronic manganese poisoning: a neuropathological study with determination of manganese distribution in the brain. Acta Neuropathol. 70:1986;273-278.
57. Olanow C.W., Tatton W.G. Etiology and pathogenesis of Parkinson's disease. Ann Rev Neursci. 22:1999;123-144.
58. Seaton T.A., Jenner P., Marsden C.D. Thioctic acid does not restore glutathione levels or protect against the potentiation of 6-hydroxydopamine toxicity induced by glutathione depletion in rat brain. J Neural Transm. 103:1996;315-329.
59. Graham J.M., Sagar H.J. A data-driven approach to the study of teterogeneity in idiopathic Parkinson's disease: identification of three distinct subtypes. Mov Disord. 14:1999;10-20.